- Home
- WOK vs LGVN Comparison
WOK vs LGVN Comparison
Compare WOK & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOK
- LGVN
- Stock Information
- Founded
- WOK 2002
- LGVN 2014
- Country
- WOK China
- LGVN United States
- Employees
- WOK N/A
- LGVN N/A
- Industry
- WOK
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- WOK
- LGVN Health Care
- Exchange
- WOK NYSE
- LGVN Nasdaq
- Market Cap
- WOK 19.6M
- LGVN 23.4M
- IPO Year
- WOK 2024
- LGVN 2021
- Fundamental
- Price
- WOK $0.84
- LGVN $1.23
- Analyst Decision
- WOK
- LGVN Strong Buy
- Analyst Count
- WOK 0
- LGVN 3
- Target Price
- WOK N/A
- LGVN $8.67
- AVG Volume (30 Days)
- WOK 3.5M
- LGVN 132.9K
- Earning Date
- WOK 02-03-2025
- LGVN 05-08-2025
- Dividend Yield
- WOK N/A
- LGVN N/A
- EPS Growth
- WOK N/A
- LGVN N/A
- EPS
- WOK N/A
- LGVN N/A
- Revenue
- WOK $11,506,440.00
- LGVN $2,225,000.00
- Revenue This Year
- WOK N/A
- LGVN N/A
- Revenue Next Year
- WOK N/A
- LGVN $24.82
- P/E Ratio
- WOK N/A
- LGVN N/A
- Revenue Growth
- WOK N/A
- LGVN 127.50
- 52 Week Low
- WOK $0.36
- LGVN $0.77
- 52 Week High
- WOK $8.45
- LGVN $6.40
- Technical
- Relative Strength Index (RSI)
- WOK N/A
- LGVN 39.93
- Support Level
- WOK N/A
- LGVN $1.25
- Resistance Level
- WOK N/A
- LGVN $1.37
- Average True Range (ATR)
- WOK 0.00
- LGVN 0.09
- MACD
- WOK 0.00
- LGVN -0.01
- Stochastic Oscillator
- WOK 0.00
- LGVN 30.00
About WOK WORK MEDICAL TECHNOLOGY GROUP LTD
WORK Medical Technology Group Ltd is engaged in manufacturing and selling medical consumables through its wholly owned subsidiaries in the People's Republic of China. The Company's main products include medical face masks, tourniquets, airways, breathing circuits, intubation accessories, anesthesia kits, oxygen masks, suction sets, laryngoscope blades, KN95 masks, and other disposable medical devices, as well as medical equipment.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.